Scientists test 'Living Drug' as new weapon against tough cancers
NCT ID NCT07409766
Summary
This is an early safety study testing a new type of cell therapy called CAR-Macrophages in patients with advanced solid tumors that have stopped responding to standard treatments. Doctors will collect a patient's own immune cells, genetically engineer them in a lab to recognize and attack cancer, and then infuse them back. The main goal is to find a safe dose and see how the body handles these modified cells, while also checking for any early signs that they might shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, 100000, China
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.